Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CytoCore Inc to acquire MEDITE


Monday, 13 Jan 2014 10:15am EST 

CytoCore Inc:Says MEDITE Group, a developer of equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology, has signed a definitive purchase agreement to be acquired by the company.Says the purchase agreement has been approved by the Board of Directors of both companies and is subject to standard and customary closing conditions and deliveries.Says transaction is currently expected to close by March 15, 2014.Says under the terms of the purchase agreement, the shareholders of MEDITE will exchange all of the issued and outstanding capital stock of MEDITE in exchange for CytoCore common stock representing approximate 80 pct of CytoCore's issued and outstanding common stock. 

Company Quote

0.022
-0.0080 -26.67%
25 Jul 2014